Clinical trial
SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
NCT00486785 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00486785 |
|---|---|
| Title | SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin |
| Official title | Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | Alfuzosin |
| Enrollment | 431 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jun 15, 2007 |
| Last update posted | Sep 30, 2009 |
| Countries | Colombia, Ecuador, Guatemala, Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: